HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYN


Mazyar Shadman, MD, MPH, on MB-106's Potential in Follicular Lymphoma

July 2nd 2022

The associate professor at Fred Hutch Cancer Center discussed data presented at the EHA 2022 Congress.

T-Charge CAR T-Cell Therapy Shows Efficacy in Multiple Myeloma

June 17th 2022

The therapy is now being evaluated in a phase 2 study.

CTX130 Shows Acceptable Safety Profile, Clinically Meaningful Responses in R/R T-Cell Lymphoma

June 16th 2022

CTX130 is also being investigated for the treatment of r/r renal cell carcinoma in a phase 1 clinical trial called COBALT-RCC (NCT04438083).

CAR T-Cell Therapy Yields High Response Rates in Follicular Lymphoma

June 16th 2022

Mustang Bio presented data on MB-106 at the 2022 EHA Congress.

Tisa-Cel Shows Durable Efficacy in Pediatric and Young Adult Patients With R/R B-Cell Acute Lymphoblastic Leukemia

June 15th 2022

Among treated patients, 42% achieved 5-year event free survival.

Dual-Targeted CAR T-Cell Therapy Continues to Show Efficacy in R/R Multiple Myeloma

June 13th 2022

GC012F also showed efficacy in B-cell non-Hodgkin lymphoma.

Anbal-Cel Shows Promising Responses in Large B-Cell Lymphoma

June 13th 2022

The CD-19 CAR T-cell therapy is developed using Curocell’s OVISTM platform.

Exa-Cel Eliminates Transfusions in TD Thalassemia and VOCs in Sickle Cell Disease

June 13th 2022

Results from the CLIMB THAL-111 and CLIMB SCD-121 trials were presented at the EHA 2022 Congress.

Axi-Cel More Efficacious With Higher Toxicity Than Tisa-Cel in Diffuse Large B-Cell Lymphoma

June 12th 2022

Response rates were significantly higher but patients had more cases of ICANS and CRS with axi-cel treatment compared to tisa-cel treatment.

Lentiviral CAR T Therapy Delivers Good Efficacy, Safety in R/R Multiple Myeloma

June 12th 2022

Participants in the trial achieved a sustained response and experienced low-grade toxicity.